Market Cap 1.05B
Revenue (ttm) 0.00
Net Income (ttm) -219.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 254,556
Avg Vol 1,077,742
Day's Range N/A - N/A
Shares Out 61.46M
Stochastic %K 46%
Beta -0.01
Analysts Strong Sell
Price Target $33.55

Company Profile

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 410 4650
Address:
One Main Street, Suite 1350, Cambridge, United States
Richmonddawg
Richmonddawg Jul. 21 at 11:23 PM
$CGEM I've made it to the big time
2 · Reply
Richmonddawg
Richmonddawg Jul. 21 at 11:20 PM
$CGEM that's me... how about that.
0 · Reply
topstockalerts
topstockalerts Jul. 17 at 9:16 PM
$CGEM the chart just keeps improving
0 · Reply
Massimo21
Massimo21 Jul. 17 at 7:46 PM
$CGEM CGEM drug working. https://x.com/muschollings/status/2077862615649312879
0 · Reply
JFais
JFais Jul. 15 at 8:30 PM
$CGEM (L) From pre-Q2 portfolio update
0 · Reply
LoneBroker
LoneBroker Jul. 10 at 11:31 PM
$CGEM $18.13 🐂 • RSI 62.63 • ATR% 6.03 • vol↓ Support & Resistance — UPDATED 2026-07-10 3 Days | Support: $17.27 – $17.27 | Resistance: $18.77 – $18.77 5 Days | Support: $17.27 – $17.27 | Resistance: $18.77 – $18.77 7 Days | Support: $17.19 – $17.19 | Resistance: $18.77 – $18.77 20 Days | Support: $11.97 – $11.97 | Resistance: $19.43 – $19.43 60 Days | Support: $11.68 – $11.68 | Resistance: $19.43 – $19.43 100 Days | Support: $11.62 – $11.62 | Resistance: $19.43 – $19.43 200 Days | Support: $5.68 – $5.68 | Resistance: $19.43 – $19.43 Momentum leans bullish with RSI at 62.63. Volatility sits at 6.03% ATR, indicating contraction. Volume shows vol↓, signaling trader attention to recent flow. -------------------------- 📌 RSI = momentum (0–100). >50 = strength, <50 = weakness 📌 ATR% = daily volatility (higher = bigger swings) 📌 Legend: 🐂 bullish • 🐻 bearish • 😐 neutral • vol↑ rising volume • vol↓ easing volume ⏳ Valid until: 1:00 PM PT
0 · Reply
JFais
JFais Jul. 10 at 9:16 PM
$CGEM (L @ 6% PW, +78% gain) $800M EV, still think this either gets bought out or revalues higher 2H 26 Multi-dose readouts for CD19 & BCMA engagers Q3 to Q4 (I&I space heating up) FLT3 T-cell engager should have a nice showing at ASH (applicable to majority of AML patients)
0 · Reply
metalcook
metalcook Jul. 7 at 6:03 PM
$CGEM no change of opinion
0 · Reply
BullJack
BullJack Jun. 26 at 2:02 PM
$CGEM $KARD $NRIX shoulda just bought all three lol
0 · Reply
metalcook
metalcook Jun. 26 at 6:46 AM
$CGEM this low volume breakout will not lead to higher highs. Retest 14$ incoming. It could be management will trigger it by dilution. They filed a shelf a month ago. That being said, bullish long term.
0 · Reply
Latest News on CGEM
Cullinan Therapeutics management to meet with BTIG

2026-07-14T19:10:17.000Z - 13 days ago

Cullinan Therapeutics management to meet with BTIG


Cullinan Therapeutics Transcript: Immunology Day 2026

Jun 10, 2026, 8:30 AM EDT - 6 weeks ago

Cullinan Therapeutics Transcript: Immunology Day 2026


Cullinan Therapeutics Slides: FY 2026

Jun 10, 2026, 8:30 AM EDT - 6 weeks ago

Cullinan Therapeutics Slides: FY 2026


Cullinan Therapeutics Press release: FY 2026

Jun 10, 2026, 8:30 AM EDT - 6 weeks ago

Cullinan Therapeutics Press release: FY 2026


Cullinan Therapeutics reports CLN-978, velinotamig data

2026-06-10T11:46:26.000Z - 6 weeks ago

Cullinan Therapeutics reports CLN-978, velinotamig data


Cullinan Therapeutics presents clinical data for CLN-978

2026-06-07T22:30:35.000Z - 7 weeks ago

Cullinan Therapeutics presents clinical data for CLN-978


Cullinan Therapeutics reports Q1 EPS (75c), consensus (85c)

2026-05-07T14:25:16.000Z - 2 months ago

Cullinan Therapeutics reports Q1 EPS (75c), consensus (85c)


Cullinan Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Cullinan Therapeutics Quarterly report: Q1 2026


Cullinan Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Cullinan Therapeutics Earnings release: Q1 2026


Cullinan jumps after UCB acquires Candid Therapeutics

2026-05-04T14:27:06.000Z - 3 months ago

Cullinan jumps after UCB acquires Candid Therapeutics


Cullinan Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Cullinan Therapeutics Proxy statement: Proxy filing


Cullinan Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Cullinan Therapeutics Proxy statement: Proxy filing


Cullinan Therapeutics Annual report: Q4 2025

Mar 10, 2026, 7:30 AM EDT - 4 months ago

Cullinan Therapeutics Annual report: Q4 2025


Cullinan Therapeutics Earnings release: Q4 2025

Mar 10, 2026, 7:30 AM EDT - 4 months ago

Cullinan Therapeutics Earnings release: Q4 2025


Cullinan Therapeutics reports Q4 EPS (77c), consensus (84c)

2026-03-10T11:11:40.000Z - 4 months ago

Cullinan Therapeutics reports Q4 EPS (77c), consensus (84c)


Cullinan Therapeutics sees cash runway into 2029

2026-03-10T11:10:51.000Z - 4 months ago

Cullinan Therapeutics sees cash runway into 2029


Cullinan Therapeutics initiated with a Buy at Citi

2026-02-17T11:00:10.000Z - 5 months ago

Cullinan Therapeutics initiated with a Buy at Citi


Cullinan Therapeutics initiated with a Buy at Guggenheim

2026-02-02T09:50:06.000Z - 6 months ago

Cullinan Therapeutics initiated with a Buy at Guggenheim


Cullinan Therapeutics Transcript: Status Update

Dec 8, 2025, 8:00 PM EST - 8 months ago

Cullinan Therapeutics Transcript: Status Update


Cullinan Therapeutics Press release: Status Update

Dec 8, 2025, 8:00 PM EST - 8 months ago

Cullinan Therapeutics Press release: Status Update


Cullinan Therapeutics Slides: Status Update

Dec 8, 2025, 8:00 PM EST - 8 months ago

Cullinan Therapeutics Slides: Status Update


Cullinan Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 9 months ago

Cullinan Therapeutics Earnings release: Q3 2025


Cullinan Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 9 months ago

Cullinan Therapeutics Quarterly report: Q3 2025


Cullinan Therapeutics Slides: Corporate Presentation

Nov 5, 2025, 6:00 PM EST - 9 months ago

Cullinan Therapeutics Slides: Corporate Presentation


Cullinan Therapeutics Slides: Corporate Presentation

Sep 9, 2025, 7:00 AM EDT - 11 months ago

Cullinan Therapeutics Slides: Corporate Presentation


Cullinan Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Earnings release: Q2 2025


Cullinan Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Quarterly report: Q2 2025


Cullinan Therapeutics Transcript: Status Update

Jun 4, 2025, 4:30 PM EDT - 1 year ago

Cullinan Therapeutics Transcript: Status Update


Cullinan Therapeutics Press release: Status Update

Jun 4, 2025, 4:30 PM EDT - 1 year ago

Cullinan Therapeutics Press release: Status Update


Cullinan Therapeutics Slides: Status Update

Jun 4, 2025, 4:30 PM EDT - 1 year ago

Cullinan Therapeutics Slides: Status Update


Cullinan Therapeutics Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Earnings release: Q1 2025


Cullinan Therapeutics Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Cullinan Therapeutics Quarterly report: Q1 2025


Cullinan Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Cullinan Therapeutics Proxy statement: Proxy Filing


Cullinan Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Cullinan Therapeutics Proxy statement: Proxy Filing


Cullinan Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Cullinan Therapeutics Earnings release: Q4 2024


Cullinan Therapeutics Annual report: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Cullinan Therapeutics Annual report: Q4 2024


Cullinan Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 9:30 AM EST - 1 year ago

Cullinan Therapeutics Quarterly report: Q3 2024


Cullinan Therapeutics Earnings release: Q3 2024

Nov 7, 2024, 9:30 AM EST - 1 year ago

Cullinan Therapeutics Earnings release: Q3 2024


Cullinan Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 7:15 AM EDT - 2 years ago

Cullinan Therapeutics Quarterly report: Q2 2024


Cullinan Therapeutics Earnings release: Q2 2024

Aug 8, 2024, 7:15 AM EDT - 2 years ago

Cullinan Therapeutics Earnings release: Q2 2024


Cullinan Therapeutics Transcript: Status Update

Jun 1, 2024, 7:30 PM EDT - 2 years ago

Cullinan Therapeutics Transcript: Status Update


Cullinan Therapeutics Slides: Status Update

Jun 1, 2024, 7:30 PM EDT - 2 years ago

Cullinan Therapeutics Slides: Status Update


Cullinan Therapeutics Proxy statement: Proxy Filing

May 16, 2024, 8:00 AM EDT - 2 years ago

Cullinan Therapeutics Proxy statement: Proxy Filing


Cullinan Therapeutics Proxy statement: Proxy Filing

May 16, 2024, 8:00 AM EDT - 2 years ago

Cullinan Therapeutics Proxy statement: Proxy Filing


Cullinan Therapeutics Quarterly report: Q1 2024

May 15, 2024, 4:30 PM EDT - 2 years ago

Cullinan Therapeutics Quarterly report: Q1 2024


Cullinan Therapeutics Earnings release: Q1 2024

May 15, 2024, 4:30 PM EDT - 2 years ago

Cullinan Therapeutics Earnings release: Q1 2024


Cullinan Therapeutics Transcript: Status Update

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Cullinan Therapeutics Transcript: Status Update


Cullinan Therapeutics Press release: Status Update

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Cullinan Therapeutics Press release: Status Update


Cullinan Therapeutics Slides: Status Update

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Cullinan Therapeutics Slides: Status Update


Cullinan Therapeutics Annual report: Q4 2023

Mar 14, 2024, 8:00 AM EDT - 2 years ago

Cullinan Therapeutics Annual report: Q4 2023


Cullinan Therapeutics Earnings release: Q4 2023

Mar 14, 2024, 8:00 AM EDT - 2 years ago

Cullinan Therapeutics Earnings release: Q4 2023


Richmonddawg
Richmonddawg Jul. 21 at 11:23 PM
$CGEM I've made it to the big time
2 · Reply
Richmonddawg
Richmonddawg Jul. 21 at 11:20 PM
$CGEM that's me... how about that.
0 · Reply
topstockalerts
topstockalerts Jul. 17 at 9:16 PM
$CGEM the chart just keeps improving
0 · Reply
Massimo21
Massimo21 Jul. 17 at 7:46 PM
$CGEM CGEM drug working. https://x.com/muschollings/status/2077862615649312879
0 · Reply
JFais
JFais Jul. 15 at 8:30 PM
$CGEM (L) From pre-Q2 portfolio update
0 · Reply
LoneBroker
LoneBroker Jul. 10 at 11:31 PM
$CGEM $18.13 🐂 • RSI 62.63 • ATR% 6.03 • vol↓ Support & Resistance — UPDATED 2026-07-10 3 Days | Support: $17.27 – $17.27 | Resistance: $18.77 – $18.77 5 Days | Support: $17.27 – $17.27 | Resistance: $18.77 – $18.77 7 Days | Support: $17.19 – $17.19 | Resistance: $18.77 – $18.77 20 Days | Support: $11.97 – $11.97 | Resistance: $19.43 – $19.43 60 Days | Support: $11.68 – $11.68 | Resistance: $19.43 – $19.43 100 Days | Support: $11.62 – $11.62 | Resistance: $19.43 – $19.43 200 Days | Support: $5.68 – $5.68 | Resistance: $19.43 – $19.43 Momentum leans bullish with RSI at 62.63. Volatility sits at 6.03% ATR, indicating contraction. Volume shows vol↓, signaling trader attention to recent flow. -------------------------- 📌 RSI = momentum (0–100). >50 = strength, <50 = weakness 📌 ATR% = daily volatility (higher = bigger swings) 📌 Legend: 🐂 bullish • 🐻 bearish • 😐 neutral • vol↑ rising volume • vol↓ easing volume ⏳ Valid until: 1:00 PM PT
0 · Reply
JFais
JFais Jul. 10 at 9:16 PM
$CGEM (L @ 6% PW, +78% gain) $800M EV, still think this either gets bought out or revalues higher 2H 26 Multi-dose readouts for CD19 & BCMA engagers Q3 to Q4 (I&I space heating up) FLT3 T-cell engager should have a nice showing at ASH (applicable to majority of AML patients)
0 · Reply
metalcook
metalcook Jul. 7 at 6:03 PM
$CGEM no change of opinion
0 · Reply
BullJack
BullJack Jun. 26 at 2:02 PM
$CGEM $KARD $NRIX shoulda just bought all three lol
0 · Reply
metalcook
metalcook Jun. 26 at 6:46 AM
$CGEM this low volume breakout will not lead to higher highs. Retest 14$ incoming. It could be management will trigger it by dilution. They filed a shelf a month ago. That being said, bullish long term.
0 · Reply
JFais
JFais Jun. 25 at 10:01 PM
$CGEM - beautiful rebound & recovery since EULAR selloff
1 · Reply
History101
History101 Jun. 24 at 6:55 PM
$CGEM i want to thank whoever it was on another ST stock discussion thread who mentioned CGEM, i'm establishing a position. GLTALs!!
1 · Reply
History101
History101 Jun. 24 at 6:54 PM
$CGEM 509 watching 6/24/2026
0 · Reply
BullJack
BullJack Jun. 24 at 7:09 AM
$KARD $CGEM $NRIX going to do some dd in these. Posting to keep on the radar
0 · Reply
Biocontrol
Biocontrol Jun. 22 at 5:34 PM
0 · Reply
DSWN
DSWN Jun. 22 at 4:44 PM
$LLY $CGEM $DFTX 2 pharma that have been holding since covid and now seeing insider buying. Check out news
0 · Reply
DSWN
DSWN Jun. 22 at 4:41 PM
$CGEM don’t understand why everyone’s bearish
0 · Reply
DSWN
DSWN Jun. 22 at 4:40 PM
$CGEM Insiders brought over a yard down in the 14 handle. I was gonna take profit over 16 but now after seeing this gonna buy more at the high and ride it up. Irma is getting a really good run right now. Also look at.$DFTX good morning both of these since Covid would like to see a decent return in the next few years.
1 · Reply
JFais
JFais Jun. 19 at 9:19 PM
Today in Chat discussing another under the radar I&I pick (& it's not $CGEM) So far like watching paint dry, but then again that's what @JoseRestonVA teaches us to do (just focus on thesis progression)
0 · Reply
JFais
JFais Jun. 19 at 9:07 PM
I&I pick we're discussing in Chat today I think is most under the radar (& it's not $CGEM) So far like watching paint dry, but then again that's what @JoseRestonVA taught me to do (just focus on thesis progression)
0 · Reply
JFais
JFais Jun. 18 at 5:27 PM
$CGEM (L) Even after the rebound, grossly undervalued at just $600M EV (FLT3 in AML alone worth that) More multi-dose data for CD19 and BCMA TCE's in Q3 & Q4, then cap off with ASH update
1 · Reply
HighRegard
HighRegard Jun. 17 at 12:14 AM
$CGEM WTF is going on with this stock ..only good news and improving price targets but terrible stock perforimance ???
1 · Reply